Galapagos Announces Encouraging New Results from Ongoing Phase 1/2 Study of CD19 CAR T-Cell Therapy, GLPG5101, in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma
Data from the ongoing Phase 1/2 ATALANTA-1 study in a heavily pretreated…
Roquette Successfully Completes Inaugural EUR 1.2 billion Bond Offering to Support its Transformative Acquisition of IFF Pharma Solutions
Roquette Successfully Completes Inaugural EUR 1.2 billion Bond Offering to Support its…